XOMA Royalty (XOMA) Competitors $36.35 -0.81 (-2.18%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$36.33 -0.02 (-0.06%) As of 10/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. XOMAO, CLDX, MNKD, BCRX, NVAX, INVA, OPK, DVAX, ZBIO, and GERNShould you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), Celldex Therapeutics (CLDX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), and Geron (GERN). These companies are all part of the "medical" sector. XOMA Royalty vs. Its Competitors XOMA Celldex Therapeutics MannKind BioCryst Pharmaceuticals Novavax Innoviva OPKO Health Dynavax Technologies Zenas BioPharma Geron XOMA (NASDAQ:XOMAO) and XOMA Royalty (NASDAQ:XOMA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings. Is XOMAO or XOMA more profitable? XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -27.57%. XOMA Royalty's return on equity of 2.63% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets XOMAN/A N/A N/A XOMA Royalty -27.57%2.63%0.97% Does the media favor XOMAO or XOMA? In the previous week, XOMA Royalty had 8 more articles in the media than XOMA. MarketBeat recorded 9 mentions for XOMA Royalty and 1 mentions for XOMA. XOMA's average media sentiment score of 1.11 beat XOMA Royalty's score of 0.21 indicating that XOMA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XOMA Royalty 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has stronger earnings & valuation, XOMAO or XOMA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$12.77MN/AN/AN/AN/AXOMA Royalty$12.77M34.40-$13.82M-$1.55-23.45 Do insiders and institutionals believe in XOMAO or XOMA? 95.9% of XOMA Royalty shares are owned by institutional investors. 9.1% of XOMA Royalty shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend XOMAO or XOMA? XOMA Royalty has a consensus target price of $69.50, indicating a potential upside of 91.20%. Given XOMA Royalty's stronger consensus rating and higher probable upside, analysts clearly believe XOMA Royalty is more favorable than XOMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00XOMA Royalty 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryXOMA Royalty beats XOMA on 9 of the 11 factors compared between the two stocks. Get XOMA Royalty News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$449.19M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-23.4521.5785.5627.61Price / Sales34.40271.42535.65201.06Price / CashN/A47.1237.9261.55Price / Book5.2310.1413.036.76Net Income-$13.82M-$52.31M$3.30B$275.88M7 Day Performance-8.07%5.14%4.35%2.81%1 Month Performance-1.12%14.68%9.50%9.24%1 Year Performance33.10%30.98%85.16%35.42% XOMA Royalty Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA Royalty4.1423 of 5 stars$36.35-2.2%$69.50+91.2%+32.4%$449.19M$12.77M-23.4510Analyst ForecastGap UpXOMAOXOMAN/A$25.61+0.3%N/A-0.6%$0.00$12.77M0.0010News CoverageShort Interest ↑CLDXCelldex Therapeutics2.1433 of 5 stars$26.19+0.2%$46.13+76.1%-10.8%$1.74B$7.02M-8.70150Positive NewsAnalyst ForecastMNKDMannKind4.0373 of 5 stars$5.39-2.5%$11.17+107.2%-15.8%$1.70B$285.50M49.00400Positive NewsAnalyst UpgradeBCRXBioCryst Pharmaceuticals4.1298 of 5 stars$7.55-1.0%$16.70+121.2%+1.1%$1.60B$450.71M-41.94530News CoverageAnalyst UpgradeNVAXNovavax4.3129 of 5 stars$8.57+0.2%$14.29+66.7%-31.7%$1.39B$682.16M3.761,990Analyst ForecastINVAInnoviva4.7717 of 5 stars$19.03+0.9%$42.75+124.6%-12.4%$1.19B$358.71M61.39100Analyst ForecastGap DownOPKOPKO Health4.2782 of 5 stars$1.47+1.4%$2.63+78.6%+5.4%$1.15B$713.10M-5.882,997Analyst ForecastDVAXDynavax Technologies4.5227 of 5 stars$9.66-1.2%$24.33+151.9%-4.2%$1.15B$316.27M-21.00350Positive NewsAnalyst ForecastZBIOZenas BioPharma1.585 of 5 stars$20.57+2.4%$36.67+78.3%N/A$846M$5M-5.79N/ATrending NewsAnalyst ForecastGap UpGERNGeron2.7787 of 5 stars$1.31+1.6%$3.79+189.0%-67.7%$823.04M$76.99M-10.0870News CoverageAnalyst Forecast Related Companies and Tools Related Companies XOMA Alternatives Celldex Therapeutics Alternatives MannKind Alternatives BioCryst Pharmaceuticals Alternatives Novavax Alternatives Innoviva Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Zenas BioPharma Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
